구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Asparaginase Erwinia chrysanthemi (Asparaginase Erwinia chrysanthemi, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, recombinant) Amgen·Acute Lymphoblastic Leukemia 134 trials |
|---|---|
Overview Program | Asparaginase Erwinia chrysanthemi (recombinant)-rywn |
Overview Company | Amgen |
Overview Modality | CGT |
Overview Target | Acute Lymphoblastic Leukemia |
Overview Indication | Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | retroviral therapy |
MoA Mechanism | and potential as a precision immunomodulator that can selectively expand and reprogram T cells |
MoA Biomarker | biomarker for ccRCC, with high, consistent expression in both primary and metastatic diseases |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | hepatotoxicity, developmental toxicity, and oxidative stress in transgenic zebrafish |
Clinical Safety signal | hepatotoxicity, developmental toxicity, and oxidative stress in transgenic zebrafish |
Clinical Selected reported efficacy | HbA1c 43.2% |
Clinical Reported ORR | 43.2% |
Clinical Result source | ClinicalTrials.gov NCT01848990 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT01848990 |
Preclinical Animal (cat.) | Mouse, In vitro |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Asparaginase Erwinia chrysanthemi (Asparaginase Erwinia chrysanthemi, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, recombinant) Amgen·Acute Lymphoblastic Leukemia 134 trials |
|---|---|
Overview Program | Asparaginase Erwinia chrysanthemi (recombinant)-rywn |
Overview Company | Amgen |
Overview Modality | CGT |
Overview Target | Acute Lymphoblastic Leukemia |
Overview Indication | Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | retroviral therapy |
MoA Mechanism | and potential as a precision immunomodulator that can selectively expand and reprogram T cells |
MoA Biomarker | biomarker for ccRCC, with high, consistent expression in both primary and metastatic diseases |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | hepatotoxicity, developmental toxicity, and oxidative stress in transgenic zebrafish |
Clinical Safety signal | hepatotoxicity, developmental toxicity, and oxidative stress in transgenic zebrafish |
Clinical Selected reported efficacy | HbA1c 43.2% |
Clinical Reported ORR | 43.2% |
Clinical Result source | ClinicalTrials.gov NCT01848990 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT01848990 |
Preclinical Animal (cat.) | Mouse, In vitro |
추천 비교
추천 비교